{{Link style|time=2015-12-11T07:39:12+00:00}}
{{distinguish|氟康唑}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458449795
| IUPAC_name = ''S''-(fluoromethyl) (6''S'',8''S'',9''R'',10''S'',11''S'',13''S'',14''S'',16''R'',17''R'')-<br>6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-<br>6,7,8,11,12,14,15,16-octahydrocyclopenta[''a'']<br>phenanthrene-17-carbothioate
| image = Fluticasone.svg
| image2 = Fluticasone ball-and-stick animation.gif

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|flovent}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = C(鼻腔內吸入)
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 鼻腔內吸入，局部塗搽

<!--Pharmacokinetic data-->
| bioavailability = 0.51% (鼻腔內)
| protein_bound = 91%
| metabolism = 鼻腔內<br>[[肝臟|肝臟]]([[:en:CYP3A4|CYP3A4]]-中介)
| elimination_half-life = 10小時
| excretion = [[腎臟|腎臟]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 90566-53-3
| CAS_supplemental = 
| CAS_number2_Ref = {{cascite|changed|??}}
| CAS_number2 = 80474-14-2
| CAS_supplemental2 = （丙酸酯）
| ATC_prefix = D07
| ATC_suffix = AC17
| ATC_supplemental = {{ATC|R01|AD08}} {{ATC|R03|BA05}}
| PubChem = 5311101
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
 | DrugBank = DB00588
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4470631
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CUT2W21N7U
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07981
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 5134
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201396

<!--Chemical data-->
 | C=22 | H=27 | F=3 | O=4 | S=1 
| molecular_weight = 444.508 g/mol
| smiles = O=C(SCF)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C
| InChI = 1/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
| InChIKey = MGNNYOODZCAHBA-GQKYHHCABQ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MGNNYOODZCAHBA-GQKYHHCASA-N
}}

'''氟替卡松'''({{lang|en|fluticasone}})為一種綜合的[[糖皮质激素|糖皮质激素]]。<ref name="Briggs_et_al2012"/>

與[[糠酸酯|糠酸酯]](furoate)或[[丙酸酯|丙酸酯]]([[:en:Propanoate|propanoate]])的合成品可以用為局部[[抗炎性|抗炎性]]、比如[[鼻炎|鼻炎]]方面：<ref name="SprattoWoods2012"/>

*[[糠酸氟替卡松|糠酸氟替卡松]]
*[[丙酸氟替卡松|丙酸氟替卡松]]([[:en:Fluticasone_propionate|Fluticasone propionate]]/氟替卡松丙酸酯)

==參見==
*[[糖皮质激素#药理作用|糖皮质激素的抗炎作用]]
*[[吸入型糖皮质激素|吸入型糖皮质激素]]
*[[皮質類固醇|皮質類固醇]]

==註釋==
{{Reflist|refs=
<ref name="Briggs_et_al2012">{{Citation
 | last1     = Briggs
 | first1    = Gerald G.
 | last2     = Freeman
 | first2    = Roger K.
 | last3     = Yaffe
 | first3    = Sumner J.
 | title     = Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk
 | publisher = Lippincott Williams & Wilkins
 | page      = 600
 | year      = 2012
 | isbn      = 1451153597
 | url       = http://books.google.com/books?id=ScPvM03B3lUC&pg=PA600
 | postscript= .
}}</ref>

<ref name="SprattoWoods2012">{{Citation
 | last1     = Spratto
 | first1    = George R.
 | last2     = Woods
 | first2    = Adrienne L.
 | title     = Delmar Nurse's Drug Handbook 2012
 | publisher = Cengage Learning
 | page      = 748
 | year      = 2012
 | isbn      = 1111310653
 | url       = http://books.google.com/books?id=x-f-kedg9ukC&pg=PA748
 | postscript= .
}}</ref>
}}

==參考文獻==
{{refbegin}}
* Jarvis B., Faulds D. (1999): Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Drugs, 57(5), 769–803. PMID 10353302
* Johnson M. (1995): The anti-inflammatory profile of fluticasone propionate. Allergy, 50(23), 11–14. PMID 7604948
* Keating G.M., McCormack P.L. (2007): Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease. Drugs, 67(16), 2383–2405. PMID 17983257
* Reynolds N.A., Lyseng-Williamson K.A., Wiseman L.R. (2005): Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs, 65(12), 1715–1734. PMID 16060707
* Spencer C.M., Jarvis B. (1999): Salmeterol/fluticasone propionate combination. Drugs, 57(6), 933–940. PMID 10400406
* Staresinic A.G., Sorkness C.A. (2000): Fluticasone propionate: A potent inhaled corticosteroid for the treatment of asthma. Expert Opin Pharmacother, 1(6), 1227-1244. PMID 11249490
* [http://www.emea.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000770/WC500028814.pdf Avamys, Zusammenfasuung der Merkmale des Arzneimittels] (PDF; 440 kB), Stand Dezember 2012, Europäische Arzneimittelagentur.
{{refend}}

{{Corticosteroids}}
{{GlaxoSmithKline}}

[[Category:糖皮质激素|Category:糖皮质激素]]
[[Category:作用于呼吸系统的药物|Category:作用于呼吸系统的药物]]
[[Category:抗喘药|Category:抗喘药]]
[[Category:有机氟化合物|Category:有机氟化合物]]
[[Category:呼吸疗法|Category:呼吸疗法]]